Ticker Report Immunic, Inc. (NASDAQ:IMUX - Free Report) - Investment analysts at Leerink Partnrs issued their Q3 2024 earnings per share estimates for shares of Immunic in a research report issued to clients and...\n more…
Ticker Report Immunic, Inc. (NASDAQ:IMUX - Get Free Report) has been assigned a consensus recommendation of "Buy" from the six research firms that are covering the company, Marketbeat reports. Five research...\n more…